Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers (BMY) Bullish Stance Reiterated at BMO Capital Post Q1 and Ahead of ASCO Inflection for Opdivo
April 29, 2015 9:01 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and $75 on Bristol-Myers Squibb Co. (NYSE: BMY) following Q1 results and as ASCO should be an inflection point for Opdivo.
commented, "On the surface, 1Q looked solid: 6% topline beat, EPS $0.71 vs. $0.51. However, the Abilify beat is short-lived, and focus remains on the IO franchise. As we expected Yervoy sales were 6% below consensus, probably reflecting increased competition, and Opdivo sales... More
